OncRef

Clinical Trial: NCT04328844

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:iOnctura
Information Provided By:iOnctura
Last Update Posted:2026-07-08

Study Overview

Brief Summary

The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)

Official Title

First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers

Conditions

Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma

Intervention / Treatment

  • Drug: IOA-244
  • Drug: Avelumab Injection
  • Drug: Pemetrexed
  • Drug: Cisplatin
  • Drug: Ruxolitinib

Other Study ID Numbers

  • IOA-244-101
  • 2019-000686-20
  • 2019

Start Date (Actual)

2020-02-25

Primary Completion Date (Actual)

2023-12-13

Study Completion Date (Estimated)

2028-03

Enrollment (Estimated)

210

Study Type

Interventional

Phase

Phase 1